1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. デバイスタイプ別スニペット
3.2. アプリケーション別スニペット
3.3. エンドユーザー別スニペット
3.4. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 神経および精神疾患の有病率の増加
4.1.2. 阻害要因
4.1.2.1. 規制上の課題
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
6. デバイスタイプ別
6.1. 導入
6.1.1. デバイスタイプ別市場規模分析および前年比成長率分析(%)
6.1.2. 市場魅力度指数（デバイスタイプ別
6.2. うつ病LTEシステム
6.2.1. はじめに
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. 1*1 tDCSプラットフォーム
6.4. Thebraindriver v2.1 デラックスシステム
6.5. DC-刺激装置モバイル
6.6. Nurostym 経頭蓋電気刺激 (tES)
6.7. その他
7. 用途別
7.1. 導入
7.1.1. 市場規模分析および前年比成長率分析（%）, アプリケーション別
7.1.2. 市場魅力度指数：用途別
7.2. うつ病
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 不安
7.4. 慢性疼痛
7.5. 認知障害
8. 用途別
8.1. はじめに
8.1.1. 用途別市場規模分析および前年比成長率分析(%)
8.1.2. 市場魅力度指数、用途別
8.2. 病院・家庭用
8.2.1. はじめに
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 神経クリニック
8.4. 外来外科センター
8.5. その他
9. 地域別
9.1. はじめに
9.1.1. 地域別市場規模分析および前年比成長率分析(%)
9.1.2. 市場魅力度指数、地域別
9.2. 北米
9.2.1. 序論
9.2.2. 主な地域別ダイナミクス
9.2.3. 市場規模分析および前年比成長率分析（％）、デバイスタイプ別
9.2.4. 市場規模分析およびYoY成長率分析（%）, アプリケーション別
9.2.5. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
9.2.6. 市場規模分析および前年比成長率分析(%)、国別
9.2.6.1. 米国
9.2.6.2. カナダ
9.2.6.3. メキシコ
9.3. ヨーロッパ
9.3.1. はじめに
9.3.2. 主な地域別動向
9.3.3. 市場規模分析および前年比成長率分析（％）、デバイスタイプ別
9.3.4. 市場規模分析およびYoY成長率分析（%）, アプリケーション別
9.3.5. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
9.3.6. 市場規模分析および前年比成長率分析(%)、国別
9.3.6.1. ドイツ
9.3.6.2. イギリス
9.3.6.3. フランス
9.3.6.4. スペイン
9.3.6.5. イタリア
9.3.6.6. その他のヨーロッパ
9.4. 南米
9.4.1. はじめに
9.4.2. 地域別主要市場
9.4.3. 市場規模分析および前年比成長率分析（％）、デバイスタイプ別
9.4.4. 市場規模分析およびYoY成長率分析（%）, アプリケーション別
9.4.5. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
9.4.6. 市場規模分析および前年比成長率分析(%)、国別
9.4.6.1. ブラジル
9.4.6.2. アルゼンチン
9.4.6.3. その他の南米諸国
9.5. アジア太平洋
9.5.1. はじめに
9.5.2. 主な地域別ダイナミクス
9.5.3. 市場規模分析および前年比成長率分析（％）、デバイスタイプ別
9.5.4. 市場規模分析およびYoY成長率分析（%）, アプリケーション別
9.5.5. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
9.5.6. 市場規模分析および前年比成長率分析(%)、国別
9.5.6.1. 中国
9.5.6.2. インド
9.5.6.3. 日本
9.5.6.4. 韓国
9.5.6.5. その他のアジア太平洋地域
9.6. 中東・アフリカ
9.6.1. 序論
9.6.2. 主な地域別ダイナミクス
9.6.3. 市場規模分析および前年比成長率分析（％）、デバイスタイプ別
9.6.4. 市場規模分析およびYoY成長率分析（%）, アプリケーション別
9.6.5. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
10. 競合情勢
10.1. 競争シナリオ
10.2. 市場ポジショニング／シェア分析
10.3. M&A分析
11. 企業プロフィール
11.1. Soterix Medical Inc.*
11.1.1. 会社概要
11.1.2. 製品ポートフォリオと内容
11.1.3. 財務概要
11.1.4. 主な展開
11.2. TheBrainDriver, LLC.
11.3. Neurocare Group AG
11.4. Brainbox Ltd.
11.5. BrainsWay
11.6. Magstim
11.7. eNeura Inc.
11.8. MagVenture A/S
11.9. Nexalin Technology
11.10. RPW Technology, LLC (*リストは除外)
12. 付録
12.1. 当社とサービスについて
12.2. お問い合わせ
The Global Transcranial Direct Current Stimulation Market reached US$ 1,346.13 million in 2023 and is expected to reach US$ 2,741.88 million by 2031 growing with a CAGR of 9.3% during the forecast period 2024-2031.
Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that involves applying a low electric current to the scalp through electrodes. Typically, this current ranges from 1 to 2 mA. tDCS operates by delivering either a positive (anodal) or negative (cathodal) current, which modulates neuronal activity in targeted brain regions. The positioning of these electrodes determines how the current flows, allowing for specific areas of the brain to be stimulated.
The mechanism of tDCS does not involve generating action potentials in neurons; instead, it produces "sub-threshold" effects that enhance or inhibit the activity of already active neurons. This can be conceptualized as tDCS boosting ongoing brain activity related to tasks or learning processes. At the cellular level, tDCS influences neuronal firing and enhances synaptic transmission, thereby promoting synaptic plasticity, which is essential for learning.
tDCS is frequently utilized in conjunction with training activities, where the stimulation amplifies the learning effects produced by the training itself. Clinical applications being explored for tDCS include treatment for conditions such as depression, schizophrenia, aphasia, addiction, epilepsy, chronic pain (including migraines and fibromyalgia), attention disorders, and motor rehabilitation. Beyond medical uses, tDCS is also applied in non-clinical settings for purposes like accelerated learning, improved focus, relaxation, and meditation.
Market Dynamics: Drivers
Increasing prevalence of neurological and psychiatric disorders
The demand for the global transcranial direct current stimulation (tDCS) market is driven by multiple factors. One of the key factors is the increasing prevalence of neurological and psychiatric disorders. The rising rates of mental health issues, including depression, anxiety, chronic pain, and cognitive impairments, have greatly impacted the expansion of the transcranial direct current stimulation (tDCS) market. tDCS is a non-invasive brain stimulation method that delivers a mild electrical current to targeted regions of the scalp, intending to influence neuronal activity and enhance neuroplasticity.
tDCS operates by modifying the excitability of neurons in specific areas of the brain. When anodal (positive) stimulation is applied, it can increase neuronal excitability, whereas cathodal (negative) stimulation can decrease it. This modulation can result in functional changes in the brain that are advantageous for treating a range of psychiatric and neurological conditions. A significant study published in the Lancet Neurology revealed that as of 2021, more than 3 billion individuals globally were affected by neurological conditions, which account for over 43% of the world's population.
Moreover, key players in the industry research activities, technological advancements, and product approvals would drive this market growth. For instance, as per HCPLive news in January 2024, a recent study has found that home-use transcranial direct current stimulation (tDCS), when combined with either a digital psychological intervention or a digital placebo, does not demonstrate superiority over sham treatment for individuals experiencing a major depressive episode. This conclusion comes from a well-structured clinical trial designed to assess the efficacy of these interventions.
Also, in a Healthcare Europe research publication in January 2024, self-administered brain stimulation, particularly through transcranial direct current stimulation (tDCS), is emerging as a novel tool for treating depression. This approach allows patients to manage their treatment at home, potentially increasing accessibility and convenience for those suffering from major depressive disorder (MDD).
Similarly, in May 2022, Flow Neuroscience announced that it had received full Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to conduct a pivotal trial in the United States using its self-managed transcranial direct current stimulation (tDCS) headset for the treatment of Major Depressive Disorder (MDD). This marks a significant step in making their innovative brain stimulation technology more accessible to patients suffering from depression.
Restraints
Factors such as regulatory challenges, the presence of alternative neuromodulation techniques, and lack of awareness among individuals are expected to hamper the market.
Market Segment Analysis
The global transcranial direct current stimulation (tDCS) market is segmented based on device type, application, end-user, and region.
The 1*1 tDCS platform segment accounted for approximately 46.8% of the global transcranial direct current stimulation (tDCS) market share
The 1*1 tDCS platform segment is expected to hold the largest market share over the forecast period. The 1x1 tDCS platform developed by Soterix Medical is a leading device in the transcranial direct current stimulation (tDCS) market, known for its precision, reliability, and customization capabilities. This platform is designed for both clinical and research applications, offering a range of unique features that set it apart from other devices.
The platform features an Open-Panel interface that streamlines the setup process and facilitates straightforward monitoring of stimulation settings. Additionally, it utilizes advanced technologies like SmartSCAN, which provides real-time monitoring of electrode contact, and TrueCurrent, which guarantees consistent current delivery during the entire stimulation session.
The Soterix Medical 1x1 tDCS device represents a significant advancement in the field of transcranial direct current stimulation (tDCS), designed specifically for clinical research and therapeutic applications. Developed by a team of clinical researchers, scientists, and biomedical engineers, the 1x1 platform is recognized for its precision and reliability in delivering tDCS protocols.
The Soterix Medical 1x1 tDCS device is recognized as a premier solution in the neuromodulation field, particularly for research and clinical applications aimed at addressing mental health issues such as depression. Its design combines user-friendly features with advanced technology and adaptability, making it an essential instrument for researchers who wish to investigate the therapeutic benefits of tDCS while ensuring safety and consistency in their studies. Consequently, it has established itself as the benchmark for accurate and reproducible tDCS in clinical trials, contributing to the advancement of knowledge regarding brain stimulation therapies.
Market Geographical Analysis
North America accounted for approximately 43.2% of the global transcranial direct current stimulation (tDCS) market share
North America region is expected to hold the largest market share over the forecast period owing to the growing prevalence of neurological and psychiatric disorders, including depression, anxiety, and chronic pain, which is a major factor driving the expansion of the transcranial direct current stimulation (tDCS) market.
There is an increasing recognition and acceptance of non-invasive treatment options among healthcare professionals and patients alike. This trend is fueling the adoption of tDCS devices in clinical settings as a viable alternative to conventional pharmacological therapies. Moreover, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, rising demand for home-use devices, innovative technological advancements, government initiatives, and ongoing research studies, product launches & approvals would propel this market growth.
For instance, in April 2022, the Florida State University College of Nursing launched the Brain Science and Symptom Management Center (BSSMC), an institute focused on interdisciplinary research to optimize pain and symptom management using brain stimulation and computer technology. The center is led by Dr. Hyochol "Brian" Ahn, who has received significant funding from the National Institutes of Health (NIH) to explore the use of transcranial direct current stimulation (tDCS) in combination with mindfulness-based meditation for self-management of clinical pain and symptoms in older adults with knee osteoarthritis.
Also, in March 2023, Sooma Medical received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its portable, patient-administered neuromodulation device aimed at treating depression. This designation is granted to innovative therapies that show significant potential to improve treatment options for severe or life-threatening conditions.
Market Segmentation
By Device Type
Depression LTE System
1*1 tDCS Platform
Thebraindriver v2.1 Deluxe System
DC-Stimulator Mobile
Nurostym Transcranial Electrical Stimulation (tES)
Others
By Application
Depression
Anxiety
Chronic Pain
Cognitive Impairments
By End-User
Hospitals & Home Use
Neurological Clinics
Ambulatory Surgical Centers
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
The rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the transcranial direct current stimulation (tDCS) market include Soterix Medical Inc., TheBrainDriver, LLC., Neurocare group AG, Brainbox Ltd, BrainsWay, Magstim, eNeura Inc., MagVenture A/S, Nexalin Technology, and RPW Technology, LLC among others.
Key Developments
In September 2024, the medical-grade neurotechnology wearable for premenstrual syndrome (PMS) refers to an innovative device designed to provide a drug-free solution for managing PMS and menstrual pain. This wearable, developed by the startup Samphire Neuroscience and named Nettle, utilizes transcranial direct current stimulation (tDCS) to target specific areas of the brain associated with mood regulation and pain perception.
In April 2024, Neurovalens, a Belfast-based neurotech startup, received FDA clearance for its Modius Stress device, a non-invasive home-use neurostimulation system designed to treat generalized anxiety disorder (GAD).
Why Purchase the Report?
To visualize the global transcranial direct current stimulation (tDCS) market segmentation based on device type, application, end-user, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points on the transcranial direct current stimulation (tDCS) market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel with key products of all the major players.
The global transcranial direct current stimulation (tDCS) market report would provide approximately 62 tables, 57 figures, and 183 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Device Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Neurological and Psychiatric Disorders
4.1.2. Restraints
4.1.2.1. Regulatory Challenges
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Device Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
6.1.2. Market Attractiveness Index, By Device Type
6.2. Depression LTE System *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. 1*1 tDCS Platform
6.4. Thebraindriver v2.1 Deluxe System
6.5. DC-Stimulator Mobile
6.6. Nurostym Transcranial Electrical Stimulation (tES)
6.7. Others
7. By Application
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Depression *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Anxiety
7.4. Chronic Pain
7.5. Cognitive Impairments
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Hospitals & Home Use *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Neurological Clinics
8.4. Ambulatory Surgical Centers
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Soterix Medical Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. TheBrainDriver, LLC.
11.3. Neurocare Group AG
11.4. Brainbox Ltd.
11.5. BrainsWay
11.6. Magstim
11.7. eNeura Inc.
11.8. MagVenture A/S
11.9. Nexalin Technology
11.10. RPW Technology, LLC (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us
❖ 世界の経頭蓋直流刺激市場に関するよくある質問(FAQ) ❖
・経頭蓋直流刺激の世界市場規模は？
→DataM Intelligence社は2023年の経頭蓋直流刺激の世界市場規模を13億4,613万米ドルと推定しています。
・経頭蓋直流刺激の世界市場予測は？
→DataM Intelligence社は2031年の経頭蓋直流刺激の世界市場規模を27億4,188万米ドルと予測しています。
・経頭蓋直流刺激市場の成長率は？
→DataM Intelligence社は経頭蓋直流刺激の世界市場が2024年～2031年に年平均9.3%成長すると予測しています。
・世界の経頭蓋直流刺激市場における主要企業は？
→DataM Intelligence社は「Soterix Medical Inc.、TheBrainDriver, LLC.、Neurocare group AG、Brainbox Ltd.、BrainsWay、Magstim、eNeura Inc.、MagVenture A/S、Nexalin Technology、RPW Technology, LLCなど ...」をグローバル経頭蓋直流刺激市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
